Last reviewed · How we verify
Silicone gel Kelo-cort™;
Silicone gel with integrated corticosteroid (likely hydrocortisone or similar) that provides topical anti-inflammatory and scar-reducing effects through moisture retention and steroid delivery to affected skin.
Silicone gel with integrated corticosteroid (likely hydrocortisone or similar) that provides topical anti-inflammatory and scar-reducing effects through moisture retention and steroid delivery to affected skin. Used for Hypertrophic scars, Keloid scars, Post-surgical scars.
At a glance
| Generic name | Silicone gel Kelo-cort™; |
|---|---|
| Sponsor | CHA University |
| Drug class | Topical corticosteroid with silicone gel base |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Kelo-cort combines medical-grade silicone gel with a corticosteroid to address hypertrophic and keloid scars. The silicone component hydrates and flattens scar tissue while occluding the wound, while the corticosteroid reduces inflammation and collagen deposition. This dual mechanism targets both the physical appearance and underlying pathophysiology of abnormal scar formation.
Approved indications
- Hypertrophic scars
- Keloid scars
- Post-surgical scars
Common side effects
- Local skin irritation
- Contact dermatitis
- Skin atrophy (with prolonged corticosteroid use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Silicone gel Kelo-cort™; CI brief — competitive landscape report
- Silicone gel Kelo-cort™; updates RSS · CI watch RSS
- CHA University portfolio CI